Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial. (PubMed, JAMA) - Oct 26, 2026 - P3 | "For participants with newly diagnosed or relapsing EGPA, rituximab was not superior to azathioprine for improving the duration of total remission during 28 months while taking prednisone at 7.5 mg/d or less. ClinicalTrials.gov Identifier: NCT03164473."
Clinical • Journal • Asthma • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Novel Coronavirus Disease • Otorhinolaryngology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Sinusitis • Vasculitis
|
|
; Alice Bérezné; Antoine Néel; Arsène Mekinian; Benjamin Terrier; Benjamin Thoreau; Chloé Comarmond-Ortoli; Claire De Moreuil; Gabriel Baron; Geoffrey Urbanski; Grégory Pugnet; Julien Campagne; Loïc Guillevin; Mohamed Hamidou; Nicolas Noël; Noémie Abisror; Pascal Cohen; Perrine Smets; Philippe Ravaud; Stéphane Jouneau; Thomas Le Gallou; Thomas Quéméneur; Xavier Puéchal; Ygal Benhamou; Yurdagül Uzunhan
|